Corticosteroid skin atrophogenicity: Assessment methods

Skin Research and Technology

Volumn 4, Issue 4, 1998, Pages 161-166

  Lee, J Y ^a,b   Maibach, H I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b The Catholic University of Korea   (South Korea)

Author keywords

Atrophogenicity of topical corticosteroid; Man; Skin atrophy; Standardization

Indexed keywords

AMCINONIDE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL BUTYRATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; DOMOPREDNATE; FLUDROXYCORTIDE; FLUMETASONE PIVALATE; FLUOCINOLONE ACETONIDE; FLUOCORTOLONE PIVALATE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; PREDNICARBATE; TRIAMCINOLONE ACETONIDE;

ABDOMEN; ARM; ARTICLE; BACK; BIOASSAY; FOREARM; HUMAN; LEG; MEDICAL LITERATURE; SHOULDER; SKIN ATROPHY; SKIN WATER LOSS; SKINFOLD THICKNESS; STANDARDIZATION; THIGH; TOPICAL DRUG ADMINISTRATION;

EID: 0031770088     PISSN: 0909752X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0846.1998.tb00104.x     Document Type: Article

References (42)

1. Marks R, Dykes PJ, Roberts E. The measurement of corticosteroid induced dermal atrophy by a radiological method. Arch Dermatol Res 1975: 253: 93-96.
2. Wilson JE. Steroid atrophy - a histological appraisal. Dermatologica 1976: 152 (suppl 1): 107-115.
3. Dykes PJ, Francis AJ, Marks R. Measurement of dermal thickness with harpenden skin caliper. Arch Dermatol Res 1976: 256: 261-263.
4. Kirby JD, Munro DD. Steroid-induced atrophy in an animal and human model. Br J Dermatol 1976: 94 (suppl 12): 111-119.
5. Alexander H, Miller DL. Determining skin thickness with pulsed ultrasound. J Invest Dermatol 1979: 72: 17-19.
6. Winter GD, Wilson L. The effect of clobetasone butyrate and other topical steroids on skin thickness of the domestic pig. Br J Dermatol 1976: 94: 545-550.
7. Winter GD, Burton JL. Experimentally induced steroid atrophy in the domestic pig and man. Br J Dermatol 1976 (suppl 12): 107-109.
8. Young JM, Yoxall BE, Wagner BN. Corticosteroid-induced dermal atrophy in the rat. J Invest Dermatol 1977: 69: 458-462.
9. Van den Hoven WE, Van den Berg TP, Korstanje C. The hair-less mouse as a model for study of local and systemic atrophogenic effects following topical application of topical steroids. Acta Derm Venereol 1991: 71: 29-31.
10. Woodbury R, Kligman AM. The hairless mouse model for assaying the atrophogenicity of topical corticosteroids. Acta Derm Venereol 1992: 72: 403-406.
11. Saarni H, Tammi M, Doherty NS. Decreased hyaluronic acid synthesis, a sensitive indicator of cortisol action. J Pharm Pharmacol 1978: 30: 200-201.
12. Cutroneo KR, Rokowski R, Counts DF. Glucocorticoids and collagen synthesis: comparison of in vivo and cell culture studies. Collagen Rel Res 1981: 1: 557-568.
13. Lubach D, Gruter H, Behl M, Narel C. Investigations on the development and regression of corticosteroid-induced thinning of the skin in various parts of the human body during and after topical application of amcinonide. Dermatologica 1989: 178: 93-97.
14. Serup J, Holm P. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. Dermatologica 1985: 170: 189-194.
15. Poelman MC, Lévêque JL, Le Gall F. Objective determination of the bioavailability of dermocorticoids - influence of the formulation. Br J Dermatol 1984 (suppl 27): 158-162.
16. McKenzie AW, Stoughton RB. Method for comparing percutanous absorption of steroids. Arch Dermatol 1962: 86: 88-90.
17. Feldmann RJ, Maibach HI. Penetration of C14 hydrocortisone through normal skin; the effect of stripping and occlusion. Arch Dermatol 1965: 91: 661-666.
18. Dykes PJ, Hill S, Marks R. Assessment of the atrophogenicity potential of corticosteoids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions. In: Christoper E, Schopf E, Kligman AM, Stoughton RB, eds. Topical corticosteroid therapy. A novel approach to safer drugs. New York: Raven Press, 1988: 111-118.
19. Serup J, Holm P, Stender IM, Pichard J. Skin atrophy and telangiectasia after topical corticosteroids as measured non-invasively with high frequency ultrasound, evaporimetry and laser Doppler flowmetry; methodological aspects including evaluation of regional difference. Bioeng Skin 1987: 3: 43-58.
20. Evans R, Cowdry EV, Nielson RE. Ageing of human skin. Anat Rec 1948: 86: 545-565.
21. Tan CY, Statham B, Marks R, Payne PA. Skin thickness measurement by pulsed ultrasound: its reproducibility, validation and variability. Br J Dermatol 1982: 106: 657-467.
22. Delfono C, Holt PJA, Marks R. Corticosteoid effects on epidermal cell size. Br J Dermatol 1978: 98: 619-623.
23. Dykes PJ, Marks R, Blakemore CB. Assessment of atrophogenicity of popularly prescribed topical corticosteroids. Br J Clin Pract 1978: 32: 345-348.
24. Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy; investigations on discontinuous application. Dermatologica 1989: 179: 67-72.
25. Meema HE, Sheppard RH, Rapoport A. Roentgenographic visualisation and measurement of skin thickness and its diagnostic application in acromegaly. Radiology 1964: 82: 411-417.
26. Black MM. A modified radiographic method for measuring skin thickness. Br J Dermatol 1969: 81: 666-669.
27. Snyder DS, Greenberg RA. Radigraphic measurement of topical corticosteroid-induced atrophy. J Invest Dermatol 1977: 69: 279-281.
28. Korting HC, Vieluf D, Kerscher M. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17 valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 1992: 42: 159-161.
29. Keiding J. Skin atrophy caused by corticosteroids. In: Wilhelm KP, Elsner P, Beradesca E, Maibach HI, eds. Bioengineering of the skin: skin surface imaging and analysis. Boca Raton: CRC Press, 1997: 345-353.
30. Kolbe L, Stoudmayer T, Kigman AM. Assessment of the atrophogenicity of corticosteroids to human skin using non-invasive methods. Skin Res Technol (in press).
31. Tan CY, Marks R, Payne P. Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning. J Invest Dermatol 1981: 76: 126-128.
32. Grove GL, Lehman PM, Leyden JJ, Kligman AM. A comparsion of methods for quantifying the atrophogenicity of topical steroids. J Invest Dermatol 1983: 80: 371(abstract).
33. Frosch PJ, Wendt H. Human methods for quantification of corticosteroid adverse effects. In: Maibach HI, Lowe NJ, eds. Models in dermatology. Vol. 1. Basel: Karger, 1985: 5-15.
34. Makki S, Agache P. Statistical analysis and three dimensional representation of the skin surface. J Soc Cosmet Chem 1984: 35: 311-325.
35. Pelfini C, Vignini M, Calligaro A. Morphometric computerized analysis as a method to assess skin atrophy caused by corticosteroids. Skin Pharmacol 1993: 6: 26-31.
36. Stenvanovic DV, Wilson L, Sparkers CG. A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate. Br J Dermatol 1977: 96: 67-70.
37. Lehmann P, Zheng P, Lavker RM, Kligman AM. Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol 1983: 81: 169-176.
38. Jablonska S, Groniowska M, Dabroswki J. Comparative evaluation of skin atrophy in man induced by topical corticoids. Br J Dermatol 1979: 100: 193-206.
39. Mark R. Methods for the assessment of skin atrophogenicity of topical corticosteroids. Dermatologica 1976:152 (suppl 1): 117-126.
40. Dykes PJ. The atrophogenicity of 1% hydrocortisone plus 10% urea. A comparison with other corticosteroids. Clin Trials J 1977: 14: 139-142.
41. Gibson JR, Kirsch JM, Darley CR, Harvey SG, Burke CA, Hanson ME. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br J Dermatol 1984: 111 (suppl 27): 204-212.
42. Kerscher MJ, Korting HC. Topical glucocorticoids of the non-fluorinated double-ester type. Acta Derm Venereol 1992: 72: 214-216.